Management of type 2 diabetes with thiazolidinediones -: Link between β-cell preservation and durability of response

被引：6

作者：

Bell, DSH ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA

来源：

ENDOCRINOLOGIST | 2004年 / 14卷 / 05期

关键词：

type; 2; diabetes; B-cell preservation; B-cell rejuvenation; thiazolidinediones;

D O I：

10.1097/01.ten.0000139039.06946.b2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The clinical onset of type 2 diabetes in most patients is typically preceded by years of insulin resistance. Type 2 diabetes develops when pancreatic beta cells are unable to produce sufficient insulin to overcome the insulin resistance. Several recent trials have shown that the thiazolidinediones (TZDs) improve both insulin sensitivity and pancreatic beta-cell function. A likely mechanism for the protective effect of TZDs is improvement in lipotoxicity. The most compelling reason to use a TZD at the earliest stage of type 2 diabetes is the unique ability of these agents to rejuvenate or decelerate the decline in pancreatic beta-cell function. This article reviews both the pathophysiology of decreased beta-cell function and the evidence for rejuvenation of pancreatic beta cells with TZD therapy in both animal and human studies.

引用

页码：293 / 299

页数：7

共 55 条

[1] Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance [J].

Ahren, B ;

Larsson, H ;

Holst, JJ .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 137 (02) :127-131

[2]

[Anonymous], 1995, Diabetes, V44, P1249

[3]

Bell D S, 2001, Endocr Pract, V7, P326

[4]

Bell D S, 2001, Endocr Pract, V7, P135

[5]

Bell David S H, 2002, Endocr Pract, V8, P271

[6] Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].

Buchanan, TA ;

Xiang, AH ;

Peters, RK ;

Kjos, SL ;

Marroquin, A ;

Goico, J ;

Ochoa, C ;

Tan, S ;

Berkowitz, K ;

Hodis, HN ;

Azen, SP .

DIABETES, 2002, 51 (09) :2796-2803

[7] Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells [J].

Buteau, J ;

Roduit, R ;

Susini, S ;

Prentki, M .

DIABETOLOGIA, 1999, 42 (07) :856-864

[8] β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].

Butler, AE ;

Janson, J ;

Bonner-Weir, S ;

Ritzel, R ;

Rizza, RA ;

Butler, PC .

DIABETES, 2003, 52 (01) :102-110

[9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[10] Endocytosis of low-density lipoprotein by human pancreatic β cells and uptake in lipid-storing vesicles, which increase with age [J].

Cnop, M ;

Grupping, A ;

Hoorens, A ;

Bouwens, L ;

Pipeleers-Marichal, M ;

Pipeleers, D .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (01) :237-244

← 1 2 3 4 5 6 →